Emerging clinical applications of RNA

Nature

Volumn 418, Issue 6894, 2002, Pages 252-258

  Sullenger, Bruce A ^a   Gilboa, Eli ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENETIC ENGINEERING; MACROMOLECULES; MEDICAL APPLICATIONS; NUCLEIC ACIDS; PROTEINS;

THERAPUTICS;

RNA;

GENE PRODUCT; NUCLEIC ACID; PROTEIN; RNA;

GENETICS; RNA;

CELL FUNCTION; CONFORMATION; GENE EXPRESSION; GENETIC ANALYSIS; MACROMOLECULE; MEDICAL RESEARCH; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; RNA SYNTHESIS; RNA TRANSLATION;

CLINICAL TRIALS; DENDRITIC CELLS; GENE EXPRESSION REGULATION; GENETICS, MEDICAL; HUMANS; IMMUNOTHERAPY; MUTATION; RNA; RNA, CATALYTIC; TRANS-SPLICING; TRANSFECTION;

EID: 0037062920     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/418252a     Document Type: Review

References (77)

1. The role of antisense RNA in gene regulation
2. Anti-mRNA: Specific inhibition of translation of single mRNA molecules
3. The use of RNAs complementary to specific mRNAs to regulate the expression of individual bacterial genes
4. Constitutive and conditional suppression of exogenous and endogenous genes by anti-sense RNA
5. Modulation of eukaryotic gene expression by complementary RNA or DNA sequences
6. Expression of chimeric tRNA-driven antisense transcripts renders NIH 3T3 cells highly resistant to Moloney murine leukemia virus replication
7. Self-splicing RNA: Autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena
8. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme
9. A small catalytic oligoribonucleotide
10. Simple RNA enzymes with new and highly specific endoribonuclease activities
11. Ribozymes and their medical implications
12. Nuclease-resistant synthetic ribozymes: Developing a new class of therapeutics
13. Small catalytic RNAs
14. Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes
15. A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA
16. A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme
17. Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA
18. mRNA localization signals can enhance the intracellular effectiveness of hammerhead ribozymes
19. Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance
20. Synthesis, deprotection, analysis and purification of RNA and ribozymes
21. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors
22. Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes
23. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
24. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells
25. U6 promoter-driven siRNA with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells
26. Expression of small interfering RNAs targeted against HIV- 1 rev transcripts in human cells
27. Effective expression of small interfering RNA in human cells
28. Group II introns designed to insert into therapeutically relevant DNA target sites in human cells
29. Ribozyme-mediated repair of defective mRNA by targeted, trans-splicing
30. Tagging ribozyme reaction sites to follow trans-splicing in mammalian cells
31. Ribozyme-mediated trans-splicing of a trinucleotide repeat
32. Induction of wild-type p 53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts
33. Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors
34. Spliceosome-mediated RNA trans-splicing as a tool for gene therapy
35. Messenger RNA repair and restoration of protein function by spliceosome-mediated RNA trans-splicing
36. Partial correction of endogenous ΔF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing
37. Promiscuity of pre-mRNA spliceosome-mediated trans splicing: A problem for gene therapy?
38. Trans-splicing ribozymes for targeted gene delivery
39. Design of highly specific cytotoxins by using trans-splicing ribozymes
40. Optimizing the substrate specificity of a group 1 intron ribozyme
41. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication
42. Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells
43. + cells from the bone marrow of human immunodeficiency virus-1-infected children
44. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase
45. In vitro selection of RNA molecules that bind specific ligands
46. Diversity of oligonucleotide functions
47. Developing aptamers into therapeutics
48. Potent 2′-amino-2′-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor
49. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain
50. Escort aptamers: A delivery service for diagnosis and therapy
51. Selection of single-stranded DNA molecules that bind and inhibit human thrombin
52. In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits
53. Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass
54. Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis
55. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys
56. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: Implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines
57. Dendritic cells and the control of immunity
58. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
59. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA
60. Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA
61. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin
62. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells
63. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
64. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells
65. HIV gag mRNA transfection of dendritic cells (DC) delivers encoded antigen to MHC class I and II molecules, causes DC maturation, and induces a potent human in vitro primary immune response
66. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: Superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells
67. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease
68. Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein MI differ in their ability to stimulate cytotoxic T lymphocytes
69. mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT)
70. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors
71. Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA
72. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro
73. Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: Implications for cervical cancer immunotherapy
74. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
75. Do human cancers express shared protective antigens? Or the necessity of remembrance of things past
76. The makings of a tumor rejection antigen
77. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors